保妇康栓联合重组人干扰素α-2b治疗HPV感染的成本-效果分析

Cost-effectiveness analysis of recombinant human interferonα-2b combined with Baofukang Suppository for treatment of HPV infection

目的 对重组人干扰素α-2b联合保妇康栓治疗人乳头瘤病毒(HPV)感染进行成本-效果分析,为临床合理用药和医疗卫生决策提供循证依据。方法 从医疗保健系统角度建立决策树模型,对重组人干扰素α-2b单用(对照组)或联合保妇康栓(每次1粒或每次2粒,分别为联合用药组1和联合用药组2)治疗HPV感染进行成本-效果分析。效果指标采用Meta分析获得HPV转阴率,成本数据根据官方网站发布的药品价格和诊疗价格获得。采用单因素敏感性分析对成本-效果分析的结果进行验证。结果 对照组、联合用药组1和联合用药组2的HPV转阴率分别为66.40%、87.00%、85.11%,对应的治疗总成本分别为1 217.20、1 303.80、1 435.38元。联合用药组1与对照组相比,增量成本效果比(ICER)为393.62元,低于1倍2021年中国人均GDP(80 976.00元),联合用药组1,即重组人干扰素α-2b联合保妇康栓(每次1粒)更具有成本-效果优势。单因素敏感性分析显示,联合用药组HPV转阴率是对ICER影响最大的因素。结论 重组人干扰素α-2b联合保妇康栓(每次1粒)治疗HPV感染更具经济性。

Objective To conduct the cost-effectiveness analysis of recombinant human interferonα-2b combined with Baofukang Suppository in treatment of Human papilloma-virus(HPV),and to provide evidence-based reference for rational drug use and medical and healthy decision-making.Methods From the perspective of the healthcare system,a decision tree model was established to analyze the cost-effectiveness of recombinant human interferonα-2b singly or combined with Baofukang Suppository(1 or 2 capsules per time for combination group 1 and combination group 2,respectively).The effectiveness was obtained through Meta-analysis,and the cost was obtained according to the drug price and diagnosis and treatment price published on the official websites.Single-factor sensitivity analysis was performed to validate the results of cost-effectiveness analysis.Results The HPV negative rates of the recombinant human interferonα-2b single group(control group),the first combination group(one capsule once time),and the second combination group(two capsule once time)were 66.40%,87.00%,and 85.11%respectively.And the corresponding total cost of treatment was separately 1217.20 yuan,1303.80 yuan,and 1435.38 yuan.Compared with the single group,the incremental cost-effect ratio(ICER)of combination group 1 was 393.62 yuan,which was less than one time the average GDP of the Chinese in 2021(80976.00 yuan).Therefore,the combination group 1,that is,recombinant human interferonα-2b combined with one capsule/time of Baofukang Suppository,has a cost-effect advantage.Single factor sensitivity analysis showed that the treatment effectiveness of these groups was the most important factor affecting the ICER.Conclusion The recombinant human interferonα-2b combined with one capsule/time of Baofukang Suppository is economical in the HPV treatment.